$CANFJul 1, 2026, 11:00 AMAI processed
Can‐Fite Phase 2a Namodenoson in pancreatic cancer meets safety endpoint, shows durable survival in a subset
AI Summary
An open‐label Phase 2a study of Namodenoson in 20 advanced pancreatic ductal adenocarcinoma patients met its primary safety endpoint and was well tolerated; in an analysis of eight third‐line patients who survived at least two months, median overall survival exceeded 5 months with 62.5% alive ≥5 months and 37.5% ≥7 months, and one second‐line patient remains alive >18 months. The dataset is small and the survival analysis excluded rapidly progressing patients, but results plus preclinical chemo‐sensitization data support Can‐Fite’s plan to advance Namodenoson into a Phase 2b combination study with chemotherapy.
Positives
- Primary safety endpoint achieved; Namodenoson was well tolerated and safety profile consistent with prior trials
- Durable survival signals in a subset of heavily pretreated patients (median OS >5 months in eight evaluable third‑line patients; some patients survived ≥7 months)
- Company plans to move Namodenoson into a Phase 2b combination trial with chemotherapy based on these findings and supporting preclinical data
Negatives
- Very small sample size (20 patients) with key survival metrics reported on an 8‑patient subset
- Open‑label, non‑randomized study with no control arm and an analysis that excluded early progressors, which can bias results
- Data are preliminary and not from a randomized efficacy trial